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Spinal cord injury (SCI) usually leads to devastating deficits 
that produce a strong impact on patients, their families and 
their communities. Neural damage may cause loss of sensory 
and motor capabilities (paraplegia or tetraplegia), infections, 
loss of bladder and bowel control, cardiac and respiratory 
dysfunctions and the development of neuropathic pain (Bap-
tiste and Fehlings, 2006; Silva et al., 2014). 
Unfortunately there is currently no standard pharmaco-
logical treatment for this condition, even though some mol-
ecules have shown protective effects in experimental animal 
models and some have entered the first stages of clinical 
trials (Kwon et al., 2011; Rabchevsky et al., 2011; Lammertse, 
2013). Only methylprednisolone reached an extended clini-
cal practice, but re-evaluation and the accumulated expertise 
have raised serious concerns about its real effectiveness and 
safety (Hurlbert, 2001, Bracken, 2012), and the use of this 
compound is being reduced in some countries (Schroeder et 
al., 2014). 
Traumatic brain injury (TBI) is a pathology that shares 
many pathological features with traumatic SCI. In TBI, like 
in SCI, several therapeutical approaches have been followed, 
including high dose methylprednisolone, but none of them 
has become a gold standard for acute care (Margulies et al., 
2009; McConeghy et al., 2012). In the last years, proges-
terone (PROG), a steroid hormone, has arisen as a strong 
candidate. PROG is widely known by its role in reproduc-
tion but also shows neuroprotective properties in different 
paradigms of brain lesion: reduces brain edema, moderates 
inflammation and preserves neurons and glial cells (Guo et 
al., 2006; Cutler et al., 2007; Stein, 2008, 2011). Because of 
the promising experimental and preclinical results obtained, 
PROG could be a pharmacological “golden bullet” for pa-
tients with severe TBI (Beauchamp et al., 2008) and, indeed, 
it has been used in two clinical trials that will enter shortly 
in phase III (Wright et al., 2007; Xiao et al., 2008). 
In SCI, the enthusiasm about PROG has been much more 
limited, even though PROG shows neuroprotective and 
remyelinating effects (De Nicola et al., 2009; Schumacher 
et al., 2012). In this pathology, we previously demonstrated 
that PROG restores the normal levels of choline acetyltrans-
ferase (ChAT) and neuronal Na, K-ATPase, enhances the 
expression of  growth-associated protein GAP-43 and BDNF, 
prevents the lesion-induced chromatolytic degeneration of 
spinal motoneurons (Labombarda et al., 2002; Gonzalez et 
al., 2004), increases the expression of pro-oligodendrogenic 
genes  (Labombarda et al., 2009) and decreases reactive glio-
sis (Labombarda et al., 2011). 
The curbed impact for progesterone in SCI may be due 
to the lack of consensus on the functional effects that fol-
low anatomical and histological improvements (Thomas et 
al., 1999; Fee et al., 2007). A closer look to published works 
shows some features that may underlie this discrepancy: 1) 
The intensity of the lesion used is not exactly the same: the 
study showing motor improvements used a moderate/severe 
injury (Thomas et al., 1999), while the study showing no 
effects used a less severe injury (Fee et al., 2007);  2) PROG 
treatment was limited in these studies to the first days after 
the lesion; and 3) in the study describing no effects of PROG 
on locomotion, motor evaluation was discontinued in the 
subacute phase of the lesion (21 days after injury), long be-
fore a plateau is reached in locomotor recovery (Basso et al., 
1995; Scheff et al., 2003).
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In contrast, literature and our own experience suggest 
that, 1) the use of a variety of complementary motor tests is 
recommended when studying gait and locomotion in treated 
rats, mostly if subtle changes are expected, like those ob-
served in mild to moderate injuries; 2) a long-lasting treat-
ment may be required to observe PROG effects (Labombarda 
et al., 2009, 2010, 2011); and 3) long survival times of treated 
animals (beyond 30–60 days) are frequently required to 
observe behavioural effects derived from the histological im-
provements induced by the treatment. 
For these reasons, and based on our previous data, we de-
cided to evaluate the functional effects of a chronic PROG 
treatment on rats submitted to a clinically relevant model 
of SCI: a moderate/severe thoracic contusion (200 kdyn, no 
dwell time), in which rats survived until the chronic phase 
(60 days after injury) (Garcia-Ovejero et al., 2014). In that 
paper, we studied anatomical and histological parameters 
using MRI, histochemistry, immunohistochemistry and ste-
reology. We also studied motor function on a weekly basis, 
using a visual open field-based locomotor scale (Basso-Bres-
nahan-Beattie scale for locomotion, score and subscore; Bas-
so et al., 1995; Basso, 2004), and an automated gait analysis 
system (Catwalk® , Hamers et al., 2001).
First, we determined the effect of PROG on the extension 
of the lesion 60 days after injury both by T2W-3D MRI and 
histology, showing that PROG reduced the volume and the 
length of the lesion. This was accompanied by a notable in-
crease in white matter preservation at the epicenter from 7% 
found in vehicle treated SCI animals to 16% preservation in 
PROG treated rats. Previous studies have shown that a small 
increase in spared white matter may result in a substantial 
recovery of locomotor function, probably by preserving 
more supraspinal and propiospinal inputs (Basso et al., 1996; 
Schucht et al., 2002; Kloos et al., 2005). PROG also increased 
oligodendrocyte numbers in the lesion epicenter, maintain-
ing up to 35% of the total number of oligodendrocytes ver-
sus the 7.5% observed in vehicle treated rats. This also was 
accompanied by a higher expression of myelin basic protein. 
Additionally, PROG preserved a higher number of axonal 
profiles at the epicenter.
Second, we studied locomotor function of the injured 
rats. We found a notable improvement in many parameters 
of locomotion induced by PROG, like the recovery of fore-
limb and hindlimb coordination, that is lost in rats after a 
thoracic spinal cord trauma (Basso et al., 1996; Kloos et al., 
2005; Koopmans et al., 2005; Hamers et al., 2006), indicating 
a better functional connection between lumbar and cervi-
cal motor control centers, that underlies a coordinated gait 
(Pearson and Rossignol, 1991; Barriere et al., 2008). Another 
parameters that PROG improved, points to a more efficient 
locomotion: less trunk instability, less hindpaw rotation, bet-
ter toe clearance, a decrease in the base of support (distance 
between the hind paws during locomotion), an increase in 
the swing phase (time that the hindpaw was not in contact 
with the glass floor), and an increase in the stride length. 
These parameters normally change in the opposite direc-
tion after SCI, and have been explained as adaptations to an 
instable gait (Hamers et al., 2001, 2006; Joosten et al., 2004; 
Hamers et al., 2006; Hendriks et al., 2006).
Treatments that produce beneficial effects after SCI 
might eventually present also undesired effects. For this, we 
checked if our treatment also conveyed a development of 
mechanical allodynia or thermal hyperalgesia. We did not 
find any of those phenomena in tests involving dynamic Von 
Frey aesthesiometry (Dolan and Nolan, 2007), Hargreaves 
test (Hargreaves et al., 1988), and CatWalk parameters nor-
mally decreased in animals developing allodynia (Deumens 
et al., 2007; Vrinten and Hamers, 2003). 
Therefore, PROG is a molecule that induces long-term 
tissue preservation and improves functional outcome after 
spinal cord contusion when administered in an appropriate 
dose and frequency. For this, and attending to the good safe-
ty results described for PROG in brain clinical trials (Wright 
et al., 2007; Xiao et al., 2008), we think that, among the dif-
ferent possible treatments that remain in a preclinical phase, 
PROG may be a good candidate to show effectiveness in SCI 
as it is doing so far in TBI. Respectfully, all we are saying is 
give progesterone a chance…
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